These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 2859857)

  • 21. Treatment of obesity with thermogenic beta-adrenoceptor agonists: studies on BRL 26830A in rodents.
    Arch JR; Ainsworth AT; Ellis RD; Piercy V; Thody VE; Thurlby PL; Wilson C; Wilson S; Young P
    Int J Obes; 1984; 8 Suppl 1():1-11. PubMed ID: 6152555
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of (-)-(R)-1-(p-hydroxyphenyl)-2-[3,4-dimethoxyphenethyl)amino]ethanol (TA-064), a new cardiotonic agent, on circulating parameters of carbohydrate and lipid metabolism in the rat.
    Inamasu M; Totsuka T; Morita T; Takeyama S
    Biochem Pharmacol; 1984 Jul; 33(14):2171-7. PubMed ID: 6147139
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 55P0110, a Novel Synthetic Compound Developed from a Plant Derived Backbone Structure, Shows Promising Anti-Hyperglycaemic Activity in Mice.
    Brunmair B; Lehner Z; Stadlbauer K; Adorjan I; Frobel K; Scherer T; Luger A; Bauer L; Fürnsinn C
    PLoS One; 2015; 10(5):e0126847. PubMed ID: 25973898
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potentiation of the anti-obesity effect of the selective beta 3-adrenoceptor agonist BRL 35135 in obese Zucker rats by exercise.
    Santti E; Huupponen R; Rouru J; Hänninen V; Pesonen U; Jhanwar-Uniyal M; Koulu M
    Br J Pharmacol; 1994 Dec; 113(4):1231-6. PubMed ID: 7889277
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The pharmacology of a new hypoglycaemic agent N-[4-(2-(2,3-dihydrobenzo(b)furan-m-carboxamido)-ethyl)-benzenesulphonyl]-N'-cyclohexylurea (NOVO CS 476). I. Pharmacological studies on the hypoglycaemic effect.
    Jorgensen KD
    Acta Pharmacol Toxicol (Copenh); 1977 Feb; 40(2):216-26. PubMed ID: 402791
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reduction of insulin resistance in obese and/or diabetic animals by 5-[4-(1-methylcyclohexylmethoxy)benzyl]-thiazolidine-2,4-dione (ADD-3878, U-63,287, ciglitazone), a new antidiabetic agent.
    Fujita T; Sugiyama Y; Taketomi S; Sohda T; Kawamatsu Y; Iwatsuka H; Suzuoki Z
    Diabetes; 1983 Sep; 32(9):804-10. PubMed ID: 6354788
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of the profiles of agonists as stimulants of the beta 3-adrenoceptor in vitro with their gastroprotective effects in the conscious rat.
    Bahl AK; Clayton NM; Coates J; Martin DP; Oakley IG; Strong P; Trevethick MA
    Br J Pharmacol; 1996 Feb; 117(3):580-586. PubMed ID: 8821552
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sustained improvement in glucose homeostasis in lean and obese mice following chronic administration of the beta 3 agonist SR 58611A.
    Williams CA; Shih MF; Taberner PV
    Br J Pharmacol; 1999 Dec; 128(7):1586-92. PubMed ID: 10602340
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of a novel GPR119 agonist, AS1269574, with in vitro and in vivo glucose-stimulated insulin secretion.
    Yoshida S; Ohishi T; Matsui T; Shibasaki M
    Biochem Biophys Res Commun; 2010 Sep; 400(3):437-41. PubMed ID: 20804735
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acute effects of the beta 3-adrenoceptor agonist, BRL 35135, on tissue glucose utilisation.
    Liu YL; Stock MJ
    Br J Pharmacol; 1995 Feb; 114(4):888-94. PubMed ID: 7773551
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The potential antidiabetic activity of some alpha-2 adrenoceptor antagonists.
    Abdel-Zaher AO; Ahmed IT; El-Koussi AD
    Pharmacol Res; 2001 Nov; 44(5):397-409. PubMed ID: 11712871
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Substrate supply for thermogenesis induced by the beta-adrenoceptor agonist BRL 26830A.
    Wilson S; Thurlby PL; Arch JR
    Can J Physiol Pharmacol; 1987 Feb; 65(2):113-9. PubMed ID: 2882828
    [TBL] [Abstract][Full Text] [Related]  

  • 33. β3-adrenoceptor-mediated increased circulating transaminase levels in mice treated with its agonist BRL 37344.
    Kasahara H; Muto S; Motokawa Y; Arisaka N; Kobayashi S; Souma S; Kuroda J
    J Toxicol Sci; 2010 Oct; 35(5):779-84. PubMed ID: 20930473
    [TBL] [Abstract][Full Text] [Related]  

  • 34. AS1907417, a novel GPR119 agonist, as an insulinotropic and β-cell preservative agent for the treatment of type 2 diabetes.
    Yoshida S; Tanaka H; Oshima H; Yamazaki T; Yonetoku Y; Ohishi T; Matsui T; Shibasaki M
    Biochem Biophys Res Commun; 2010 Oct; 400(4):745-51. PubMed ID: 20816753
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of BTS 67 582, a novel antidiabetic agent, in normal and diabetic rats.
    Jones RB; Dickinson K; Anthony DM; Marita AR; Kaul CL; Buckett WR
    Br J Pharmacol; 1997 Mar; 120(6):1135-43. PubMed ID: 9134227
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improvement of metabolic disorders and visceral fat obesity by the beta 3-adrenoceptor agonist (R*,R*)-(+/-)-methyl-4-[2-[2-hydroxy-2 -(3-chlorophenyl)ethylamino]propyl]-phenoxyacetate hydrobromide (BRL35135A) in genetically obese rodents.
    Hashimoto K; Nagao Y; Ida K; Takeda M; Murakami N; Kato K; Mizota M
    Biochem Pharmacol; 1996 Nov; 52(10):1529-35. PubMed ID: 8937467
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glucose transporter in insulin sensitive tissues of lean and obese mice. Effect of the thermogenic agent BRL 26830A.
    Le Marchand-Brustel Y; Olichon-Berthe C; Grémeaux T; Tanti JF; Rochet N; Van Obberghen E
    Endocrinology; 1990 Dec; 127(6):2687-95. PubMed ID: 2249621
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hypoglycemic activity of 1-alpha-(3,4-dimethoxyphenethylaminomethyl) -2-hydroxybenzylalcohol 1/2 fumarate (TA-078) in the mouse, rat and dog.
    Iwai H; Inamasu M; Totsuka T; Shimazaki T; Morita T; Takeyama S
    Biochem Pharmacol; 1983 Mar; 32(5):849-55. PubMed ID: 6340689
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic effects of berberine in impaired glucose tolerance rats and its influence on insulin secretion.
    Leng SH; Lu FE; Xu LJ
    Acta Pharmacol Sin; 2004 Apr; 25(4):496-502. PubMed ID: 15066220
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chronic treatment with BRL 35135 potentiates the action of insulin on lipid metabolism.
    Virtanen KA; Rouru J; Hänninen V; Savontaus E; Rouvari T; Teirmaa T; Koulu M; Huupponen R
    Eur J Pharmacol; 1997 Aug; 332(2):215-8. PubMed ID: 9286624
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.